Cytochrome P4502C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient

被引：28
|
作者：
Stempak, D
Bukaveckas, BL
Linder, M
Koren, G
Baruchel, S
机构：
[1] Hosp Sick Children, Div Hematol Oncol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Div Clin Pharmacol & Toxicol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
[3] Univ Louisville, Dept Pathol & Lab Med, Louisville, KY 40292 USA
[4] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[5] Hosp Sick Children, Div Hematol Oncol, New Agent & Innovat Therapy Program, Toronto, ON M5G 1X8, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 78卷 / 03期
关键词：
D O I：
10.1016/j.clpt.2005.06.005
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：309 / 310
页数：2
相关论文
共 50 条
  • [31] Crystallization of human P4502C9
    Wester, MR
    Stout, CD
    Schoch, G
    Yano, JK
    Johnson, EF
    FASEB JOURNAL, 2003, 17 (04): : A609 - A609
  • [32] Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines
    Yilmaz, N
    Erbagci, AB
    Aynacioglu, AS
    ACTA BIOCHIMICA POLONICA, 2001, 48 (03) : 775 - 782
  • [33] Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolisers
    Verstuyft, C
    Morin, S
    Robert, A
    Loriot, MA
    Beaune, P
    Jaillon, P
    Becquemont, L
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R113 - R113
  • [34] Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers
    Verstuyft, C
    Morin, S
    Robert, A
    Loriot, MA
    Beaune, P
    Jaillon, P
    Becquemont, L
    PHARMACOGENETICS, 2001, 11 (08): : 735 - 737
  • [35] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538
  • [36] Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
    Scordo, MG
    Aklillu, E
    Yasar, U
    Dahl, ML
    Spina, E
    Ingelman-Sundberg, M
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) : 447 - 450
  • [37] Cytochrome P4502C9 activity in end-stage renal disease
    Dreisbach, AW
    Japa, S
    Gebrekal, AB
    Mowry, SE
    Lertora, JJL
    Kamath, BL
    Rettie, AE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (05) : 475 - 477
  • [38] Tamoxifen inhibits cytochrome P4502C9 activity in breast cancer patients
    Boruban, M. C.
    Yasar, U.
    Babaoglu, M. O.
    Sencan, O.
    Bozkurt, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (04) : 421 - 424
  • [39] The risk of myocardial infarction in patients with reduced activity of cytochrome P4502C9
    Visser, Loes E.
    van Schaik, Ron H. N.
    Danser, Alexander H. Jan
    Hofman, Albert
    Witteman, Jacqueline C. M.
    van Duijn, Cornelia M.
    Uitterlinden, Andre G.
    Pols, Huibert A. P.
    Stricker, Bruno H. Ch.
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 473 - 479
  • [40] In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P4502C9:: correlation with CYP2C9 genotype and in-vivo pharmacokinetics
    Tang, CY
    Shou, MG
    Rushmore, TH
    Mei, Q
    Sandhu, P
    Woolf, EJ
    Rose, MJ
    Gelmann, A
    Greenberg, HE
    De Lepeleire, I
    Van Hecken, A
    De Schepper, PJ
    Ebel, DL
    Schwartz, JI
    Rodrigues, AD
    PHARMACOGENETICS, 2001, 11 (03): : 223 - 235
12345